Evidence map›Paper›PMID 40228860›Full record

ArticleBMJ open2025

STatin TReatment for COVID-19 to Optimise NeuroloGical recovERy (STRONGER): study protocol for a randomised, open label clinical trial in patients with persistent neurological symptoms after COVID-19 infection.

Carlos Delfino, Cheryl Carcel, Xiaolei Lin, Paula Muñoz-Venturelli, Sharon L Naismith, Mark Woodward, Ruth Peters, Nirupama Wijesuriya, Meng Law, Ian H Harding and 7 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04904536 (An International, Investigator Initiated and Conducted, Pragmatic Clinical Trial to Determine Whether 40mg Atorvastatin Daily Can Improve Neurocognitive Function in Adults With Long COVID Neurological Symptoms), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04904536 phase3active not recruitingnot on this map

An International, Investigator Initiated and Conducted, Pragmatic Clinical Trial to Determine Whether 40mg Atorvastatin Daily Can Improve Neurocognitive Function in Adults With Long COVID Neurological Symptoms

TypeinterventionalSponsorThe George InstituteRan2022 to 2025Enrolled190ConditionsNeurocognitive Impairment, MildArmsAtorvastatin, Standard Care
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Carlos DelfinoCentro de Estudios Clínicos, Instituto de Ciencias e Innovación en Medicina (ICIM), Universidad del Desarrollo Facultad de Medicina Clínica Alemana, Las Condes, Chile.ORCID http://orcid.org/0000-0002-4834-2718
Cheryl CarcelFaculty of Medicine, University of New South Wales, The George Institute for Global Health, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8942-953X
Xiaolei LinData science, Fudan University, Shanghai, China.
Paula Muñoz-VenturelliCentro de Estudios Clínicos, Instituto de Ciencias e Innovación en Medicina (ICIM), Universidad del Desarrollo Facultad de Medicina Clínica Alemana, Las Condes, Chile.ORCID http://orcid.org/0000-0003-1869-2255
Sharon L NaismithCharles Perkins Centre and The University of Sydney, The University of Sydney Brain and Mind Centre, Camperdown, New South Wales, Australia.
Mark WoodwardFaculty of Medicine, University of New South Wales, The George Institute for Global Health, Sydney, New South Wales, Australia.
Ruth PetersFaculty of Medicine, University of New South Wales, The George Institute for Global Health, Sydney, New South Wales, Australia.
Nirupama WijesuriyaFaculty of Medicine, University of New South Wales, The George Institute for Global Health, Sydney, New South Wales, Australia.
Meng LawDepartment of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Ian H HardingDepartment of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Xia WangFaculty of Medicine, University of New South Wales, The George Institute for Global Health, Sydney, New South Wales, Australia.
Julian ElliottDepartment of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Karin LederDepartment of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-1368-1039
Owen HutchingsRoyal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Ximena StecherDepartamento de Imagenología, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Clinica Alemana de Santiago SA, Vitacura, Metropolitan Region, Chile.ORCID http://orcid.org/0000-0002-7962-9519
Sophia ZoungasDepartment of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-2672-0949
Craig S AndersonFaculty of Medicine, University of New South Wales, The George Institute for Global Health, Sydney, New South Wales, Australia canderson@georgeinstitute.org.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIncreasing awareness of the high frequency, wide spectrum and disabling nature of symptoms that can persist following COVID-19 infection has prompted the investigation of management strategies. Our study aims to determine the effectiveness of atorvastatin on cognitive function, physical activity, mood, health-related quality of life and features of neurovascular impairment and neuroinflammation in adults with ongoing neurological symptoms after COVID-19 infection. METHODS AND ANALYSIS: The STatin TReatment for COVID-19 to Optimise NeuroloGical recovERy study is an ongoing international, investigator-initiated and conducted, multicentre, prospective, randomised, open label, blinded endpoint trial with fixed time points for outcome assessments. A total of 410 participants with long covid neurological symptoms were planned to be randomly assigned to either the intervention group to receive 40 mg atorvastatin for 12 months or to a control group of no treatment, on top of usual care. ETHICS AND DISSEMINATION: This study protocol was designed, implemented and reported, in accordance with the International Conference on Harmonisation guidelines for Good Clinical Practice, the National Health and Medical Research Council of Australia, the National Statement on Ethical Conduct in Human Research and with the ethical principles laid down in the World Medical Association Declaration of Helsinki. Central ethics committee approval was obtained from Sydney Local Health District Royal Prince Alfred Hospital Ethics (No: X21-0113 and 2021/ETH00777 10) in Australia. Site-specific ethics committee approvals were obtained elsewhere before any local study activities. All participants provided written informed consent. TRIAL REGISTRATION NUMBER: The study protocol is registered at Clinicaltrials.gov (NCT04904536).

Indexed as

AtorvastatinCOVID-19COVID-19 Drug TreatmentHydroxymethylglutaryl-CoA Reductase InhibitorsNervous System DiseasesAdultCognitionFemaleHumansMaleMiddle AgedMulticenter Studies as TopicProspective StudiesQuality of LifeRandomized Controlled Trials as TopicSARS-CoV-2AtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsClinical ProtocolsCOVID-19Post-Acute COVID-19 SyndromeProtocols & guidelines

Identifiers

PMID40228860
PMCPMC11997840

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.